Baicalin
(Synonyms: 黄芩苷; Baicalein 7-O-β-D-glucuronide) 目录号 : GN10018
A flavonoid with diverse biological activities
Cas No.:21967-41-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Cell experiment: |
SH-SY5Y cell lines are cultured in RPMI-1640 medium supplemented with 15% fetal bovine serum at 37°C in an air atmosphere containing 95% air and 5% CO2 with a saturated humidity. Upon a confluence of 60~70%, the SH-SY5Y cells are divided into: (i) control group, incubated in RPMI-1640 medium; (ii) thrombin group, which is subject to thrombin induction (40 U/L) for 6 h based on our pre-experiment; and (iii) Baicalin groups, which are treated by Baicalin (5 μM, 10 μM, or 20 μM) for 2 h before induction of thrombin. Cell viability is measured using MTT assay. Briefly, 15 μL of the MTT solution (5 mg/mL) is added to each well and incubated for 4 h at 37°C. After removing the supernatant, 80 μL DMSO are added into each well. The absorbance is measured at 492 nm using a microplate reader. All experiments are performed in triplicate[2]. |
|
Animal experiment: |
Rats[1]Male Wistar rats weighing 200-250 g are used. Rats are randomly divided into five groups of six rats each: (i) sham group; (ii) IR+saline group; (iii) IR+Baicalin (1 mg/kg) group; (iv) IR+Baicalin (10 mg/kg) group; and (v) IR+Baicalin (100 mg/kg) group. Renal IRI is induced by clamping the left renal artery for 45 min plus a right nephrectomy. Rats are anesthetized through an intraperitoneal injection of pentobarbital sodium (40 mg/kg body weight). After a median abdominal incision, the left renal arteries are clamped for 45 min with serrefine. After clamp removal, adequate restoration of blood flow is checked before abdominal closure. The right kidney is then removed. Sham-operated animals underwent the same surgical procedure without clamping[1]. |
|
References: [1]. Lin M, et al. The protective effect of Baicalin against renal ischemia-reperfusion injury through inhibition of inflammation and apoptosis. BMC Complement Altern Med. 2014 Jan 13;14:19. |
|
Baicalin is a flavonoid glycoside isolated from Scutellaria baicalensis. Baicalin reduces the expression of NF-κB.
Baicalin protects against ischemia-reperfusion injury (IRI) by altering the production of various mediators, including reactive oxygen species (ROS), Toll-like receptor (TLR)2 and TLR4, NF-κB, Bax, and Bcl-2. Baicalin treatment inhibits the increased expression of the proinflammatory cytokines TLR2/4, MyD88, p-NF-κB, and p- IκB, as well as increase the expression of IκB protein, an NF-κB inhibitor, with the degree of inhibition positively related to the dosage of Baicalin[1]. Cell viability is determined by MTT assay. Compared with control cells, cell viability is significantly decreased in SH-SY5Y cells treated with thrombin. Pre-treatment with Baicalin (5, 10, 20 μM) increases cell viability in a dose-dependent manner compared with cells treated thrombin alone[2].
Baicalin pretreatment dose-dependently protects against a loss of renal function, with the two higher doses (10 and 100 mg/kg) significantly decreasing Scr and blood urea nitrogen (BUN) concentrations. Tissue injury, as assessed using a 0-3 point scoring system, is lower for the Baicalin treated groups than for the ischemia-reperfusion (IR)+saline group. Compared with the sham group, malondialdehyde (MDA) content is only slightly up-regulated and the SOD activity is only slightly down-regulated in rats treated with 10 and 100 mg/kg Baicalin, indicating that Baicalin abrogates the increase in oxidative stress following reperfusion[1].
References:
[1]. Lin M, et al. The protective effect of Baicalin against renal ischemia-reperfusion injury through inhibition of inflammation and apoptosis. BMC Complement Altern Med. 2014 Jan 13;14:19.
[2]. Ju XN, et al. Baicalin protects against thrombin induced cell injury in SH-SY5Y cells. Int J Clin Exp Pathol. 2015 Nov 1;8(11):14021-7.
| Cas No. | 21967-41-9 | SDF | |
| 别名 | 黄芩苷; Baicalein 7-O-β-D-glucuronide | ||
| 化学名 | (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid | ||
| Canonical SMILES | C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O | ||
| 分子式 | C21H18O11 | 分子量 | 446.37 |
| 溶解度 | DMSO: ≥ 100 mg/mL (224.03 mM） | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2403 mL | 11.2015 mL | 22.4029 mL |
| 5 mM | 0.4481 mL | 2.2403 mL | 4.4806 mL |
| 10 mM | 0.224 mL | 1.1201 mL | 2.2403 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。